Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: blankmind who wrote (629)	11/6/1999 5:45:00 PM
From: Gary Korn	Read Replies (1) \| Respond to of 10345

From the YHOO thread: Alzheimer vaccine by: Bio_guyo 11/6/1999 4:17 pm EST Msg: 3666 of 3669 Rumor has it that the IND has been filed. Consequently, phase I will begin when FDA okays IND - agency has 30 days to respond to an IND filing. So, unless the company botched the IND, patients will begin getting the amyloid beta-protein vaccine by the end of this month. Enrollment should be quite easy, as there are millions of patients, and no available drugs directed at the disease process.

To: blankmind who wrote (629)	11/7/1999 1:06:00 AM
From: Gary Korn	Read Replies (1) \| Respond to of 10345

Merrill update on 11/5: Unjustified Weakness, In Our View Reason for Report: Stock Weakness. (Short and Long Term BUY maintained) Investment Highlights: ú Stock weakness appears to be renewed concerns about Elan?s accounting, which we believe is unfounded. ú We remind investors that the SEC has thoroughly reviewed and approved Elan?s financial statements through June 1999. ú We expect Elan to announce that it intends to acquire Axogen, its off-balance sheet R&D vehicle shortly for completion by year-end. This is assumed in our estimates. ú Our 1999 and 2000 estimates are unchanged. Our tentative estimate for 2001 is $2.00 (+29%) per share based on our assumption that Elan will have introduced four new drugs by that time. ú We believe that the stock is undervalued. We expect a rebound in the stock price once FDA filings and approvals occur over the next few months.